FDA inspection
Wuhan Humanwell Likang Pharmaceutical Co., Ltd.: FDA inspection ending Aug 23, 2019
FDA inspection 1113116 · Voluntary Action Indicated (VAI) · Wuhan
Key facts
| Inspection ID | 1113116 |
|---|---|
| Firm | Wuhan Humanwell Likang Pharmaceutical Co., Ltd. |
| FEI number | 3014919801 |
| Address | 98 Wuhan, Shendun 2nd Road, Donghu New Technology Development Zone |
| City | Wuhan |
| Fiscal year | 2019 |
| Inspection end date | Aug 23, 2019 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Generic Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data